相关实验视频

Updated: Jan 11, 2026

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

泽因化物A-D:来自Caralluma adenensis的前糖化物

Ola E Abdel-Sattar¹, Manal M Sabry², Riham A El-Shiekh²

¹Herbal Department, Egyptian Drug Authority Giza Egypt.

|November 17, 2025

概括

在传统的也门医学中使用的植物Caralluma adenensis中发现了四种新的pregnane糖化物,zeinosides A-D. 这些化合物可能具有未来治疗应用的潜力,支持植物.

科学领域:

自然产品化学自然产品化学
植物化学植物化学
药用植物研究药用植物研究

背景情况:

,原产于也门,具有多样化的传统医疗用途.
这种植物以其抗糖尿病,抗,抗炎,抗寄生虫和抗发烧的特性而闻名.

研究的目的:

从Caralluma adenensis中分离和描述新型孕妇糖化物.
用先进的光谱方法阐明分离化合物的化学结构.

主要方法:

甲醇提取Caralluma adenensis的. 这是一个非常好的方法.
使用色谱技术分离化合物.
通过1D和2DNMR,LC-ESI-IT-TOF-MS和IR光谱学来阐明结构.
使用NOESY相关性进行立体化学分析.

主要成果:

四种新的pregnane糖化物,zeinosides A-D,被分离和鉴定出来.
泽伊诺化物A-D具有聚氧化C-21类固醇骨架,具有特定的或修饰.
糖分类包括β-d-数字和β-d-葡萄糖,每种化合物含有不同数量的糖单位.

结论:

这项研究扩大了卡拉卢马属内已知的化学多样性.
泽伊诺化物A-D代表潜在的新型治疗剂.
这些发现可能为Caralluma adenensis的传统医疗应用提供科学依据.

更多相关视频

Enema of Traditional Chinese Medicine for Patients with Severe Acute Pancreatitis

Enema of Traditional Chinese Medicine for Patients with Severe Acute Pancreatitis

Published on: January 27, 2023

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...